L-Dopa Pharmacokinetic Profile with Effervescent MelevodopaCarbidopa versus Standard-Release LevodopaCarbidopa Tablets in Parkinson’s Disease: A Randomised Study
المؤلفون المشاركون
Stocchi, Fabrizio
Vacca, Laura
Grassini, Paola
Pawsey, Stephen
Whale, Holly
Marconi, Stefano
Torti, Margherita
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-06-10
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objectives.
To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating Parkinson’s disease.
Few studies assessed the pharmacokinetics of carbidopa to date.
Methods.
This was a single-centre, randomized, double-blind, double-dummy, two-period crossover study.
Patients received V1512 (melevodopa 100 mg/carbidopa 25 mg) or L-dopa 100 mg/carbidopa 25 mg, 7 doses over 24 hours (Cohort 1), 4 doses over 12 hours (Cohort 2), or 2 doses over 12 hours in combination with entacapone 200 mg (Cohort 3).
Pharmacokinetic parameters included area under the plasma-concentration time curve (AUC), maximum plasma concentration ( C m a x ), and time to C m a x ( t m a x ).
Results.
Twenty-five patients received at least one dose of study medication.
L-dopa absorption tended to be quicker and pharmacokinetic parameters less variable after V1512 versus L-dopa/carbidopa, both over time and between patients.
Accumulation of L-dopa in plasma was less noticeable with V1512.
Carbidopa exposure and interpatient variability was lower when V1512 or L-dopa/carbidopa was given in combination with entacapone.
Both treatments were well tolerated.
Conclusions.
V1512 provides a more reliable L-dopa pharmacokinetic profile versus standard-release L-dopa/carbidopa, with less drug accumulation and less variability.
This trial is registered with ClinicalTrials.gov NCT00491998.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Stocchi, Fabrizio& Vacca, Laura& Grassini, Paola& Pawsey, Stephen& Whale, Holly& Marconi, Stefano…[et al.]. 2015. L-Dopa Pharmacokinetic Profile with Effervescent MelevodopaCarbidopa versus Standard-Release LevodopaCarbidopa Tablets in Parkinson’s Disease: A Randomised Study. Parkinson’s Disease،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1075868
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Stocchi, Fabrizio…[et al.]. L-Dopa Pharmacokinetic Profile with Effervescent MelevodopaCarbidopa versus Standard-Release LevodopaCarbidopa Tablets in Parkinson’s Disease: A Randomised Study. Parkinson’s Disease No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1075868
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Stocchi, Fabrizio& Vacca, Laura& Grassini, Paola& Pawsey, Stephen& Whale, Holly& Marconi, Stefano…[et al.]. L-Dopa Pharmacokinetic Profile with Effervescent MelevodopaCarbidopa versus Standard-Release LevodopaCarbidopa Tablets in Parkinson’s Disease: A Randomised Study. Parkinson’s Disease. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1075868
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1075868
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر